Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MSBase- An international Registry dedicated to evaluating outcomes data in Multiple Sclerosis

Trial Profile

MSBase- An international Registry dedicated to evaluating outcomes data in Multiple Sclerosis

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 15 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cladribine (Primary) ; Fingolimod (Primary) ; Natalizumab (Primary) ; Ocrelizumab (Primary) ; Glatiramer acetate; Interferon
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms MSBase
  • Most Recent Events

    • 13 Oct 2023 Results evaluating the comparative effectiveness of ocrelizumab, a high efficacy DMT, versus interferon or glatiramer acetate in pwMS over the age of 60, are presented at the 9th Triennial joint meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis.
    • 13 Oct 2023 Results by identifying patients from this study to explore relapse and disability outcomes comparing those retreated with 3rd cycle of alemtuzumab vs those receiving different high efficacy DMT (ocrelizumab,ofatumumab, natalizumab),stratifying by time from 2nd alemtuzumab cycle to the next relapse, presented at the 9th Triennial joint meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis
    • 09 Nov 2022 Results analyzing cost effectiveness by deriving data from GLIMPSE, a real-world study evaluating treatment effectiveness of these oral DMTs in RMS patients in MSBase registry, presented at the 25th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top